🇺🇸 FDA
Pipeline program

ADZENYS XR-ODT

NT0202.1009

Approved small_molecule terminated

Quick answer

ADZENYS XR-ODT for Attention Deficit Hyperactivity Disorder is a Approved program (small_molecule) at AYTU BIOPHARMA, INC with 1 ClinicalTrials.gov record(s).

Program details

Company
AYTU BIOPHARMA, INC
Indication
Attention Deficit Hyperactivity Disorder
Phase
Approved
Modality
small_molecule
Status
terminated

Clinical trials